Kibow, Vetoquinol Expand Azodyl Pact

Kibow Biotech and Vetoquinol S.A. have announced an exclusive licensing and marketing agreement for Kibow Biotics.

Kibow Biotech Inc. and Vetoquinol S.A. signed an exclusive world-wide licensing and marketing agreement for Kibow Biotics.

Kibow Biotech Inc. of Philadelphia and Vetoquinol S.A. of Paris signed an exclusive world-wide licensing and marketing agreement for Kibow Biotics, marketed as Azodyl. Vetoquinol had acquired U.S. and Canadian marketing rights of the product for veterinary applications, marketed as Azodyl, in June 2006.

“This is an outstanding opportunity for us to reinforce our presence in the field of cardio-nephrology, one of our key strategic domains of development,” said Chrisitian Schivrel, group director for business development for Vetoquinol.

The microbial, probiotic supplement is formulated for the reduction of azotemia in dogs and cats with renal failure. Kibow reports the product has been shown to reduce the nitrogenous uremic toxin buildup, and thereby may prevent further kidney damage.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.